RAKOVINA THERAPEUTICS INC (RKV.CA) Stock Income Statement
TSX-V:RKV - TSX Venture Exchange - CA75103L1013 - Common Stock - Currency: CAD
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-6-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 3.05M | 2.48M | 2.82M | 2.48M | 200.00K | |||
| Research and Development | 1.48M | 1.14M | 1.41M | 1.50M | N/A | |||
| Selling, General, and Administrative Expenses | 997.90K | 810.40K | 868.30K | 970.00K | 200.00K | |||
| Operating Income | -3.05M | -2.48M | -2.82M | -2.48M | -200.00K | |||
| Interest Income/Expense | -237.50K | -87.00K | 26.30K | 0.00 | 10.00K | |||
| Other Income/Expense | N/A | -43.80K | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | 0.00 | -3.05M | N/A | |||
| Income Before Taxes | -3.31M | -2.61M | -2.79M | -5.52M | -190.00K | |||
| Net Income | -3.31M | -2.61M | -2.79M | -5.52M | -190.00K | |||
| EBITDA | -2.52M | -1.95M | -2.28M | -2.07M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.04 | -0.04 | -0.04 | -0.10 | -0.10 | |||
| Statistics | ||||||||
All data in CAD